Retinoic acid (RA), a derivative of vitamin A (retinol), exerts a wide range of biological effects on cell proliferation and differentiation, and embryonic development. The pleiotropic effects of RA are mediated by its binding to specific nuclear RA receptors (RARs) which function as transcription factor after ligand-dependent activation. To date, three species of human RARs (α, β and γ) have been described. In several hundreds of publications as to retinoic acid (RA) action, Dr. Zhu in earlier years (1990-91) postulate molecular model of RA action, which reported in Voice of America, 1992 [1]; presented at 2^nd and 3^rd biomedical world congress, Dubai, UAE, 2013, 2014 [2,3] and published early in JCCM (EBSCO cited), 2007, 2010 [4,5], in Curr Pharm Biotechnol, vol 14 issue 9, 2013 [6], later updated in Univ J Pharm Res, vol 4 issue 6, 2018 [7], in Am J Biomed Sci & Res, vol 3 issue 2, 2019 [8] and recent updated in Med J Clin Trials Case Stud, and in EC Endocrinol and Metab Res, 2020 [9-11].

References

1. Zhu G. “Oncogenic receptor hypothesis (1989-91)”. Voice of America 12 (1992): 31.
2. Zhu G. “A furgher study of patients with advanced cancers after chemotherapy with traditional medicine”. The Journal of Contingencies and Crisis Management (Hong Kong)11 (2007): 618-623.
3. Zhu G. “Use of chemotherapy and traditional chinese medicine for advanced cancer: A retrospective study of 68 patients (1993～2010)”. The Journal of Contingencies and Crisis Management (HongKong)6 (2010): 343-360.
4. Zhu G. “A pilot study of small dosage of chemotherapy and traditional medicine in advanced cancers: report of twenty-four cases (abstract)”. Proceeding of 2^nd biotech- nology world congress, Dubai, UAE, February18-21 (2013): 98.
5. Zhu G. “Discovery of the molecular basis of retinoic acid action (retinoid signaling)- A genetic regulation of eukaryotes in transcription (abstract)”. Proceeding of 3^rd biotech- nology world congress, Dubai, UAE, February10-12 (2014): 97-98.
6. Zhu G., et al. “Novel treatment of acute promyelocytic leukemia: As2O3,retinoic acid and retinoid pharmacology”. Current Pharmaceutical Biotechnology 9 (2013): 849- 858.
7. Zhu G., et al. “Vitamin A, retinoic acid and tamibarotene, a front toward its advances: a review”. Universal Journal of Pharmaceutical Research 6 (2018): 38-48.
8. Zhu G. “Vitamin A and its derivatives- retinoic acid and retinoid pharmacology”. American Journal of Biomedical Science and Research 2 (2019): 162-177.
9. Zhu G. “A retrospective analytical approach to treatment outcome of 40 anemias”. Medical Journal of Clinical Trials and Case Studies 1 (2020): 000254.
10. Zhu G. “How I treat anemia”. EC Endocrinology and Metabolic Research 4 (2020): 20-27.
11. Zhu G. “APL: retinoic acid and retinoid pharmacology, a breakthrough trials today”. Journal of Endocrinology and Thyroid Research 4 (2019): 555643.
12. Rousselot P., et al. “The PML-RARa gene products of the t (15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells”. Oncogene2 (1994): 545-551.
13. Raelson JV., et al. “The PML/RARa oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells”. Blood8 (1996): 2826-2832.
14. Grignani Fr., et al. “Effects on differentiation by the promyelocytic leukemia pml/RAR alpha protein dimerization and RAR alpha DNA binding domains”. The EMBO Journal 10 (1996): 4949-4958.
15. He LZ., et al. “Distinct interactions of PML-RARa and PLZF-RARa with co-repressors determine differential response to RA in APL”. Nature Genetics 18 (1998): 126-
16. Duprez E., et al. “A mutated PML/RARA found in the retinoid maturation resistant NB4 subclone,NB4-R2,blocks RARA and wild-type PML/RARA transcriptional activities”. Leukemia 14 (2000): 255-
17. Segalla S., et al. “Retinoic acid receptor alpha fusion to PML affects its transcriptional and chromatin-remodeling properties”. Molecular and Cellular Biology 23 (2003): 8795-8808.
18. Jing Y., et al. “The cleavage product delta PML-RARa contribute to all-trans retinoic acid-mediated differentiation in acute promyelocytic leukemia celks”. Oncogene 22 (2003): 4083-
19. Villa R., et al. “The methyl-CpG binding protein MBD is required for PML-RARa fusion”. Proceedings of the National Academy of Sciences of the United States of America 5 (2006): 1400-1405.
20. Matsushita H., et al. “In vivo analysis of the role of aberrant histone deacetylase recruitment and RARa blockade in pathogenesis of acute promyelocytic leukemia”. Journal of Experimental Medicine 203 (2006): 821-
21. Marstrand TT., et al. “A conceptional framework for the identification of candidate drugs and drug targets in acute promyelocytic leukemia”. Leukemia 24 (2010): 1265-12
22. Lallemand BV and De The H. “A new omcoprotein catabolism pathway”. Blood 13 (2010): 2200-2201.
23. Dos Santos GA., et al. “Synergy against PML-RARa: targeting transcription, proteolysis, differentiation and self-renewal in acute promyelocytic leukemia”. Journal of Experimental Medicine 13 (201): 2793-2802.
24. Podhorecka M and Macheta A. “Acute promyelocytic leukemia- modern approach to disease pathogenesis and differentiation treatment”. Postępy Higieny i Medycyny Doświadczalnej 67 (2013): 1083-108
25. De Braekeleer E., et al. “RARA fusion gene in acute promyelocytic leukemia: A review”. Expert Review of Hematology 7 (2014): 347-3
26. Vitaliano-Prunier A., et al. “Clearance of PML/ RARA-bound promotes suffice to initiate APL differentiation”. Blood25 (2014): 3772-3780.
27. Noguera NJ., et al. “PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity”. Oncotarget 41 (2016): 66386-66397.
28. Wang GJ., et al. “PML/RARa blocks the differentiation and promotes the proliferation of acute promyelocytic leukemia through activating MYB expression by transcriptional and epigenetic regulation mechanisms”. Journal of Cellular Biochemistry 2 (2018): 1210-1220.
29. Keeshan K., et al. “Co-operative leukemogenesis in acute myeloid leukemia and acute promyelocytic leukemia reveals C/EBP as a common target of TRIB1 and PML/RARA”. Haematologica10 (2016): 1228-1236.
30. Onodera M., et al. “Overexpression of retinoic acid receptor alpha suppresses myeloid cell differentiation at the promyelocyte stage”. Oncogene 11 (1995): 12.
31. Tsai S and Collins SJ. “A dominant negative retinoic acid receptor blocks neutrophil differentiation at promyelocytic stages”. Proceedings of the National Academy of Sciences of the United States of America 15 (1993): 7153-7157.
32. Early E., et al. “Transgenic expression of PML/RAR alpha impairs myelopoiesis”. Proceedings of the National Academy of Sciences of the United States of America 15 (1996): 7900-7904.
33. Altabef M., et al. “A retrovirus carrying the promyelocyte- retinoic acid receptor PML/RARa fusion gene transforms haematopoietic progenitors in vitro and induces acute leukemia”. The EMBO Journal 15 (1996): 2007.
34. Brown D., et al. “A PML/RARa transgenic initiates murine acute promyelocytic leukemia”. Proceedings of the National Academy of Sciences of the United States of America 14 (1997): 1547.
35. He LZ., et al. “Acute leukemia with promyelocytic features in PML/RARa transgenic mice”. Proceedings of the National Academy of Sciences of the United States of America 94 (1997): 5302-5307.
36. Grisolano JL., et al. “Altered myloid development and acute leukemia in transgenic mice expressing PML-RARa under control of cathepsin G regulatory sequence”. Blood 89 (1997): 376.
37. Pollock JL., et al. “A bcr-3 isoforms of RAR alpha- PML potentiates the development of PML-RAR alpha-driven acute promyelocytic leukemia”. Proceedings of the National Academy of Sciences of the United States of America 28 (1999): 15103.
38. Du C., et al. “Overexpression of wild-type retinoic acid receptor alpha recapitulates retinoic acid-sensitive transformation of primary myeloid progenitors by acute promyelocytic leukemia RARA-fusion gene”. Blood 94 (1999): 793.
39. Kelly LM., et al. “PML/RAR alpha and FLT3-ITD induces APL-like disease in a mouse model”. Proceedings of the National Academy of Sciences of the United States of America 99 (2002): 8283-828
40. Minucci S., et al. “PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors”. Blood8 (2002): 2989-2995.
41. Sukhai MA., et al. “Myeloid leukemia with promyelocytic features in transgenic mice expressing hCG-NuMA-RAR alpha”. Oncogene3 (2004): 665-678.
42. Deepa S., et al. “PML-RARa and Dnmt 3a1 cooperate in vitro to promote acute promyelocytic leukemia”. Cancer Research 70 (2010): 8792-
43. Veeraraghavan J., et al. “Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers”. Nature Communications 5 (2014): 4577.
44. Yue W., et al. “Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis”. Steroids 78 (2013): 161-
45. Santen R., et al. “Estrogen mediation of breast tumor formation involves estrogen receptor-dependent,as well as independent,genotoxic effects”. Annals of the New York Academy of Sciences 1155 (2009): 132-
46. Ye Q., et al. “Identification of a novel FAS/ER-alpha fusion transcript expressed in human cancer cells”. Biochimica et Biophysica Acta 3 (2000): 373-377.
47. Berger R., et al. “Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells”. Cancer Research 64 (2004): 8867-88
48. Shi XB., et al. “The oncogenic potential of a prostatic cancer-drived androgen receptor mutant”. The Prostate 67 (2007): 591-
49. Izumi K., et al. “Androgen receptor roles in the development of benign prostate hyperplasia”. The American Journal of Pathology 182 (2013): 1942-19
50. Singh RR and Kumar R. “Steroid hormone receptor signaling in tumorigenesis”. Journal of Cellular Biochemistry 96 (2005): 490-
51. Schrader M., et al. “RXR-dependent and RXR-independent transactivation by retinoic acid receptors”. Nucleic Acids Research 5 (1993): 1231-1237.
52. Doucar V., et al. “The PML-retinoic acid receptor alpha translocation converts the receptor from an inhibitor to a retinoic acid- dependent activator of transcription factor AP-1”. Proceedings of the National Academy of Sciences of the United States of America 20 (1993): 9345-9349.
53. Humbert M., et al. “The tumor duppressor gene DAPK2 is induced by the myeloid transcript factors PU.1 and C/EBPa during granulocytic differentiation but repressed by PML-RARa in APL”. Journal of Leukocyte Biology 1 (2014): 83-93.
54. Liquori A., et al. “Acute promyelocytic leukemia: A constellation of molecular events around a single PML-RARA fusion gene”. Cancers 12 (2020): 624.
55. Heyman RA., et al. “9-cis retinoic acid is a high affinity ligand for the retinoid X receptor”. Cell2 (1992): 397-406.
56. Isakson P., et al. “Autophagy contributes to therapy- induced degradation of the PML/RARA oncoprotein”. Blood 13 (2010): 2324-2331.
57. Trocoli A., et al. “ATRA-induced upregulation of Beclin 1 prolongs the life span of differentiated acute promyelocytic leukemia cells”. Autophagy10 (2011): 1108-1114.
58. Yoshida H., et al. “Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARa) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia, possible role of the proteasome pathway”. Cancer Research 13 (1996): 2945-2948.
59. Tomita A., et al. “Mechanism of action and resistance to all-trans retinoic acid(ATRA) and arsenic trioxide(As2O3) in acute promyelocytic leukemia”. International Journal of Hematology 97 (2013): 717-7
60. Johnson BS., et al. “Retinoid X receptor(RXR) agonist-induced activation of dominant-negative RXR-retinoic acid receptor a403 heterodimers is developmentally regulated during myeloid differentiation”. Molecular and Cellular Biology 19 (1999): 3372-
61. Soignet SL., et al. “Clinical study of 9-cis retinoic acid (LGD 1057) in acute promyelocytic leukemia”. Leukemia10 (1998): 1518-1521.
62. He LZ., et al. “Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia”. Journal of Clinical Investigation 108 (2001): 1321-
63. Warrell JrRP., et al. “Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor histone deacetylase”. Journal of the National Cancer Institute 60 (1998): 1621-16
64. McMullin MF., et al. “Prolonged molecular remission in PML- RARa-positive acute promyelocytic leukemia treated with minimal chemotherapy followed by maintenance including the histone deacetylase inhibitor sodium valproate”. Leukemia 19 (2005): 1676-
65. Tomita A., et al. “Fusion protein of retinoic acid receptor alpha with promyelocytic leukemia protein or promyelocytic leukemia zinc finger protein recruits N-CoR-TBLR1 corepressor complex to repress transcription in vivo”. The Journal of Biological Chemistry 278 (2003): 30788-30795